SignatureFD’s Corbus Pharmaceuticals CRBP Stock Holding History

SignatureFD’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6	Closed	-$1K	–	2625
2020 Q2	$1K	Buy	+6	New	+$1.21K	﹤0.01%	2276

Other funds holding CRBP

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

SignatureFD's CRBP Position: Q3 2020 in Review

SignatureFD sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 6 shares — an estimated $1K sold.

SignatureFD first reported a position in CRBP in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

SignatureFD reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
SignatureFD sold 6 Corbus Pharmaceuticals shares in Q3 2020, an estimated $1K.
SignatureFD first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 1 quarter.
SignatureFD's Corbus Pharmaceuticals position peaked at $1K in Q2 2020.
122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on SignatureFD's 13F filing for Q3 2020, filed 3 Nov 2020.